HalfLifeDBEvidence before certainty.

Carfentanil evidence profile

The direct pharmacokinetic study in the current source set was performed in goats.

Category: synthetic-opioid · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References2Linked studies, labels, reviews, or identity records described below

Carfentanil: evidence and interpretation notes

Why HalfLifeDB does not plot Carfentanil

The direct pharmacokinetic study in the current source set was performed in goats. Given carfentanil potency and the absence of a defensible human cohort in these citations, an animal-derived model would be both misleading and unnecessarily risky.

What each source contributes

  • PubChem: Carfentanil. This identity record confirms names and compound identity and does not supply a human half-life.
  • Pharmacokinetics of carfentanil and naltrexone in domestic goats (Capra hircus). This preclinical study documents species-specific disposition or assay work and is not translated into a typical human estimate.

For Carfentanil, the decision to withhold a curve turns on the limits visible in Pharmacokinetics of carfentanil and naltrexone in domestic goats (Capra hircus). This preclinical study documents species-specific disposition or assay work, but it is not translated into a typical human estimate.

What evidence would change the page

For Carfentanil, stronger evidence means more than detection or biological activity: it means a clearly reported human elimination estimate tied to one analyte and route. That numerical bridge is absent from Pharmacokinetics of carfentanil and naltrexone in domestic goats (Capra hircus).

InterpretationCategory context and evidence limits

synthetic opioid context

Synthetic opioid pages often require careful evidence labeling because potency, toxicology risk, and pharmacokinetic evidence quality can vary widely across compounds.

  • Half-life is not a potency or overdose-risk measure.
  • Some entries may rely on limited or indirect data.
  • Public-health and toxicology context should be separated from the simple curve.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

1 PubMed0 PMC0 DailyMed1 PubChem
  1. Identity record PubChem Compound Summary: Carfentanil.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
  2. Research abstract PubMed: Pharmacokinetics of carfentanil and naltrexone in domestic goats (Capra hircus).
    Animal pharmacokinetic study; included because public human pharmacokinetic data are limited.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.